X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (109) 109
pkc412 (104) 104
index medicus (98) 98
hematology (64) 64
acute myeloid-leukemia (56) 56
oncology (56) 56
staurosporine - analogs & derivatives (56) 56
mutation (49) 49
animals (45) 45
tyrosine kinase inhibitor (43) 43
female (38) 38
leukemia (38) 38
internal tandem duplication (37) 37
male (36) 36
fms-like tyrosine kinase 3 - genetics (35) 35
leukemia, myeloid, acute - drug therapy (33) 33
acute myeloid leukemia (32) 32
fms-like tyrosine kinase 3 - antagonists & inhibitors (31) 31
leukemia, myeloid, acute - genetics (31) 31
mice (31) 31
flt3 (30) 30
protein kinase inhibitors - pharmacology (30) 30
midostaurin (29) 29
staurosporine - pharmacology (29) 29
acute myelogenous leukemia (28) 28
middle aged (27) 27
cell line, tumor (25) 25
pharmacology & pharmacy (25) 25
antineoplastic agents - pharmacology (24) 24
protein kinase inhibitors - therapeutic use (24) 24
adult (23) 23
aged (23) 23
aml (23) 23
cancer (23) 23
mutations (23) 23
cell proliferation - drug effects (22) 22
apoptosis (21) 21
apoptosis - drug effects (21) 21
hemic and lymphatic diseases (21) 21
tyrosine (21) 21
antineoplastic agents - therapeutic use (20) 20
chemotherapy (20) 20
kinase inhibitor pkc412 (20) 20
wild-type (20) 20
kinase inhibitor (19) 19
phase-i (19) 19
activating mutation (18) 18
midostaurin pkc412 (18) 18
imatinib (17) 17
sorafenib (17) 17
imatinib mesylate (16) 16
in-vitro (16) 16
abridged index medicus (15) 15
article (15) 15
kinases (15) 15
systemic mastocytosis (15) 15
fms-like tyrosine kinase 3 - metabolism (14) 14
proteins (14) 14
staurosporine - administration & dosage (14) 14
embryonic structures (13) 13
health aspects (13) 13
hematology, oncology and palliative medicine (13) 13
hemic and immune systems (13) 13
leukemia, myeloid, acute - pathology (13) 13
mastocytosis, systemic - drug therapy (13) 13
phosphorylation (13) 13
staurosporine - therapeutic use (13) 13
cells (12) 12
drug resistance, neoplasm - genetics (12) 12
leukemia, myeloid, acute - metabolism (12) 12
c-kit (11) 11
genetic aspects (11) 11
niacinamide - analogs & derivatives (11) 11
prognosis (11) 11
protooncogene c-kit (11) 11
young adult (11) 11
analysis (10) 10
drug resistance (10) 10
drug resistance, neoplasm (10) 10
gene (10) 10
inhibitor pkc412 (10) 10
leukemia, myeloid, acute - enzymology (10) 10
proto-oncogene proteins c-kit - genetics (10) 10
research (10) 10
resistance (10) 10
risk myelodysplastic syndrome (10) 10
signal transduction (10) 10
therapy (10) 10
tyrosine kinase inhibitors (10) 10
activation (9) 9
adult patients (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (9) 9
bcr-abl (9) 9
dasatinib (9) 9
drug resistance, neoplasm - drug effects (9) 9
fluids and secretions (9) 9
gene mutations (9) 9
mastocytosis (9) 9
myelodysplastic syndrome (9) 9
patients (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 03/2017, Volume 129, Issue 11, pp. 1420 - 1427
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2016, Volume 374, Issue 26, pp. 2530 - 2541
Journal Article
PHARMACOTHERAPY, ISSN 0277-0008, 12/2017, Volume 37, Issue 12, pp. 1586 - 1599
Acute myeloid leukemia (AML), a clonal hematologic malignancy that results in bone marrow failure, is the most common acute leukemia in adults (median age of... 
midostaurin | acute myeloid leukemia | FLT3-mutant AML | PHARMACOLOGY & PHARMACY | tyrosine kinase inhibitor | PKC412
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 8, pp. 1061 - 1075
Journal Article
by Zhu, YY and Wang, CJ and Zhou, Y and Ma, N and Zhou, JW
JOURNAL OF CELLULAR PHYSIOLOGY, ISSN 0021-9541, 12/2018, Volume 233, Issue 12, pp. 9437 - 9446
The purpose of this study was to evaluate the anti-head and neck squamous cell carcinoma (anti-HNSCC) cell activity by C6 ceramide and multikinase inhibitor... 
CANCER-CELLS | PHYSIOLOGY | VIVO | INDUCED APOPTOSIS | C6-CERAMIDE | ACUTE MYELOID-LEUKEMIA | PKC412 | MTOR | CELL BIOLOGY | IN-VITRO | HNSCC | MOLECULAR TARGETED THERAPIES | C6 ceramide | TYROSINE KINASE INHIBITOR | multikinase inhibitor | PHASE-I
Journal Article
Blood, ISSN 0006-4971, 03/2011, Volume 117, Issue 12, pp. 3294 - 3301
Journal Article
Haematologica, ISSN 0390-6078, 10/2018, Volume 103, Issue 11, pp. 1760 - 1771
Mastocytosis is a term used to denote a group of rare diseases characterized by an abnormal accumulation of neoplastic mast cells in various tissues and... 
DASATINIB BMS-354825 | WILD-TYPE | GEMTUZUMAB OZOGAMICIN | ACTIVATING MUTATION | MIDOSTAURIN PKC412 | C-KIT MUTATION | TYROSINE KINASE INHIBITOR | MYELOID-LEUKEMIA | HUMAN MAST-CELLS | HEMATOLOGY | BONE-MARROW LESIONS | Review
Journal Article
Leukemia, ISSN 0887-6924, 2012, Volume 26, Issue 9, pp. 2061 - 2068
Journal Article
PHARMACOTHERAPY, ISSN 0277-0008, 12/2017, Volume 37, Issue 12, pp. E124 - E124
Acute myeloid leukemia (AML), a clonal hematologic malignancy that results in bone marrow failure, is the most common acute leukemia in adults (median age of... 
midostaurin | acute myeloid leukemia | FLT3-mutant AML | PHARMACOLOGY & PHARMACY | tyrosine kinase inhibitor | PKC412
Journal Article
Blood, ISSN 0006-4971, 06/2012, Volume 119, Issue 22, pp. 5133 - 5143
Internal tandem duplication (ITD) of the fms-related tyrosine kinase-3 (FLT3) gene occurs in 30% of acute myeloid leukemias (AMLs) and confers a poor... 
FLT3 TYROSINE KINASE | INTERNAL TANDEM DUPLICATION | ADULT PATIENTS | ACTIVATING MUTATION | INHIBITOR PKC412 | ALDEHYDE DEHYDROGENASE-ACTIVITY | ACUTE MYELOGENOUS LEUKEMIA | TISSUE INHIBITOR | RISK MYELODYSPLASTIC SYNDROME | PROGNOSTIC-SIGNIFICANCE | HEMATOLOGY | Niacinamide - analogs & derivatives | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Neoplasm Transplantation | Humans | Middle Aged | Aldehyde Dehydrogenase - biosynthesis | Matrix Metalloproteinase 15 - genetics | Male | Transplantation, Heterologous | Bone Marrow - enzymology | Gene Expression Profiling | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Benzenesulfonates - adverse effects | Janus Kinase 3 - biosynthesis | fms-Like Tyrosine Kinase 3 - genetics | Leukemia, Myeloid, Acute - enzymology | Pyridines - adverse effects | Time Factors | Antineoplastic Agents - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Protein Structure, Tertiary | Pyridines - administration & dosage | Leukemia, Myeloid, Acute - pathology | Aldehyde Dehydrogenase - genetics | Gene Expression Regulation, Leukemic | Mice, SCID | fms-Like Tyrosine Kinase 3 - metabolism | Matrix Metalloproteinase 15 - biosynthesis | Drug Resistance, Neoplasm - genetics | Animals | Bone Marrow - pathology | Janus Kinase 3 - genetics | Mice, Inbred NOD | Mice | Mutation | Drug Resistance, Neoplasm - drug effects | Leukemia, Myeloid, Acute - genetics
Journal Article
CHIMIA, ISSN 0009-4293, 08/2019, Volume 73, Issue 7-8, pp. 561 - 570
The efficacy and side-effects of drugs do not just reflect the biochemical and pharmacodynamic properties of the parent compound, but often comprise of... 
Nilotinib | Imatinib | Metabolite | SAFETY | Midostaurin | PROTEIN-KINASE INHIBITOR | ACUTE MYELOID-LEUKEMIA | ABL | CHEMISTRY, MULTIDISCIPLINARY | DISCOVERY | PKC412 | Leukaemia | STRUCTURAL BIOLOGY | PHARMACOKINETICS | DRUG METABOLITES
Journal Article
American Journal of Pathology, The, ISSN 0002-9440, 2009, Volume 175, Issue 6, pp. 2416 - 2429
Recent data suggest that the signal transducer and activator of transcription (STAT)5 contributes to differentiation and growth of mast cells. It has also been... 
Pathology | DASATINIB BMS-354825 | WILD-TYPE | SELECTIVE INHIBITOR | DNA-BINDING | PROTOONCOGENE C-KIT | CONSTITUTIVE ACTIVATION | BCR-ABL | MUTATION | PATHOLOGY | KINASE INHIBITOR PKC412 | SIGNAL TRANSDUCER | Life Sciences | Human health and pathology
Journal Article